Page 67 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Rogers et al. J Transl Med (2020) 18:203 Page 13 of 19

AS: data analysis and interpretation of manuscript writing. BM: data analysis 10. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation
and interpretation of manuscript writing. All authors read and approved the and epidemiology of 2019 novel coronavirus: implications for virus
f nal manuscript. origins and receptor binding. Lancet. 2020;395(10224):565–74.
11. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia
Funding outbreak associated with a new coronavirus of probable bat origin.
Personalized Stem Cells, Inc. providing partial funding for the writing, editing Nature. 2020;579(7798):270–3.
and publishing of this manuscript. 12. Hof mann M, Kleine‑Weber H, Krüger N, Müller M, Drosten C, Pöhlmann
S. The novel coronavirus 2019 (2019‑nCoV) uses the SARS‑coronavirus
Availability of data and materials receptor ACE2 and the cellular protease TMPRSS2 for entry into target
Not applicable. cells. bioRxiv. 2020. https ://doi.org/10.1101/2020.01.31.92904 2.
13. Organization WH. Report of the WHO‑China Joint Mission on Corona‑
Ethics approval and consent to participate virus Disease 2019 (COVID‑19) 2020. https ://www.who.int/docs/defau
Not applicable. lt‑sourc e/coron aviru se/who‑china ‑joint ‑missi on‑on‑covid ‑19‑f nal
‑repor t.pdf. Accessed 24 Feb 2020.
Consent for publication 14. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological f nd‑
Not applicable. ings of COVID‑19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 2020;8(4):420–2.
Competing interests 15. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J
CR, RH declared equity in Personalized Stem Cells, Inc., but there is no conf ict Med. 2000;342(18):1334–49.
of interest. The other authors indicated no potential conf icts of interest. 16. Donahoe M. Acute respiratory distress syndrome: a clinical review. Pulm
Circ. 2011;1(2):192–211.
Author details 17. Baron RM, Levy BD. Recent advances in understanding and treating
2
1 Personalized Stem Cells, Inc, Poway, CA, USA. Center for Stem Cell Research ARDS [version 1;referees: 2 approved]. F1000Res. 2016;5(F1000 Faculty
and Regenerative Medicine, Tulane University School of Medicine, New Rev):725. https ://doi.org/10.12688 /f1000 resea rch.7646.1.
3
Orleans, LA, USA. Department of Surgery, Oregon Health and Science 18. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan
4
University, Portland, OR, USA. State Key Laboratory for Diagnosis and Treat‑ E, et al. Acute respiratory distress syndrome: the Berlin def nition. JAMA.
ment of Infectious Diseases, National Clinical Research Center for Infectious 2012;307(23):2526–33.
Diseases, The First Af liated Hospital, College of Medicine, Zhejiang University, 19. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz‑Granados N,
5
Hangzhou 310003, China. Treatment and Research Center for Infectious Cooper A, et al. Functional disability 5 years after acute respiratory
6
Diseases, The Fifth Medical Center, Beijing 100039, China. Calidi Biotherapeu‑ distress syndrome. N Engl J Med. 2011;364(14):1293–304.
7
tics, Inc., San Diego, CA, USA. Department of Radiation Medicine and Applied 20. Karbing DS, Kjaergaard S, Smith BW, Espersen K, Allerod C, Andreas‑
Sciences, Moores UCSD Cancer Center, San Diego, CA, USA. sen S, et al. Variation in the PaO 2 /FiO 2 ratio with FiO 2 : mathemati‑
cal and experimental description, and clinical relevance. Crit Care.
Received: 26 April 2020 Accepted: 14 May 2020 2007;11(6):R118.
21. Hughes KT, Beasley MB. Pulmonary manifestations of acute lung
injury: more than just dif use alveolar damage. Arch Pathol Lab Med.
2017;141(7):916–22.
22. Horie S, Gonzalez HE, Laf ey JG, Masterson CH. Cell therapy in acute
References respiratory distress syndrome. J Thorac Dis. 2018;10(9):5607–20.
1. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal 23. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health
stem cells interact with tissue immune responses. Trends Immunol. and inf ammation. Nat Rev Immunol. 2013;13(3):159–75.
2012;33(3):136–43. 24. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al.
2. Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, Prone positioning in severe acute respiratory distress syndrome. N Engl
et al. Mesenchymal stem cell‑based therapy of inf ammatory lung J Med. 2013;368(23):2159–68.
diseases: current understanding and future perspectives. Stem cells 25. Papazian L, Forel JM, Gacouin A, Penot‑Ragon C, Perrin G, Loundou
international. 2019;2019:4236973. A, et al. Neuromuscular blockers in early acute respiratory distress
3. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. syndrome. N Engl J Med. 2010;363(12):1107–16.
Antibacterial ef ect of human mesenchymal stem cells is mediated 26. Tonelli AR, Zein J, Adams J, Ioannidis JP. Ef ects of interventions on
in part from secretion of the antimicrobial peptide LL‑37. Stem Cells. survival in acute respiratory distress syndrome: an umbrella review of
2010;28(12):2229–38. 159 published randomized trials and 29 meta‑analyses. Intensive Care
4. Khatri M, Richardson LA, Meulia T. Mesenchymal stem cell‑derived Med. 2014;40(6):769–87.
extracellular vesicles attenuate inf uenza virus‑induced acute lung 27. Duggal AGA, Ratnapalan M, et al. Pharmacological treatments for
injury in a pig model. Stem Cell Res Therapy. 2018;9(1):17. acute respiratory distress syndrome: systematic review. Minera Anest.
5. Hosseini M, Yousef fard M, Aziznejad H, Nasirinezhad F. The ef ect of 2015;81:567–88.
bone marrow‑derived mesenchymal stem cell transplantation on 28. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic
allodynia and hyperalgesia in neuropathic animals: a systematic review of bone marrow. Analysis of precursor cells for osteogenic and hemat‑
with meta‑analysis. Biol Blood Marrow Transplant. 2015;21(9):1537–44. opoietic tissues. Transplantation. 1968;6(2):230–47.
6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of 29. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641–50.
patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 30. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper‑Cortenbach I,
2020;395(10223):497–506. Marini FC, et al. Clarif cation of the nomenclature for MSC: The Inter‑
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics national Society for Cellular Therapy position statement. Cytotherapy.
of 138 hospitalized patients with 2019 novel coronavirus‑infected 2005;7(5):393–5.
pneumonia in Wuhan. Jama: China; 2020. 31. Dominici M, Le Blanc K, Mueller I, Slaper‑Cortenbach I, Marini F, Krause
8. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission D, et al. Minimal criteria for def ning multipotent mesenchymal stromal
dynamics in Wuhan, China, of novel coronavirus‑infected pneumonia. cells. The International Society for Cellular Therapy position statement.
N Engl J Med. 2020;382:1199–207. Cytotherapy. 2006;8(4):315–7.
9. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of 32. Caplan AI. Mesenchymal stem cells: time to change the name! Stem
ACE2‑mesenchymal stem cells improves the outcome of patients with cells Transl Med. 2017;6(6):1445–51.
COVID‑19 pneumonia. Aging Dis. 2020;11:216–28. 33. Mazini L, Rochette L, Amine M, Malka G. Regenerative capacity of adi‑
pose derived stem cells (ADSCs), comparison with mesenchymal stem
cells (MSCs). Int J Mol Sci. 2019;20(10):2523.